Stay updated with breaking news from Eric Kelsic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric...
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric...
Scientists at Harvard Medical School and Technion-Israel Institute of Technology have built a giant petri dish to visually demonstrate how bacteria move as they become immune to drugs.
Published May 6, 2021 Permission granted by Eric Kelsic / Dyno Therapeutics Dyno Therapeutics, a Harvard University spinout working to improve gene therapy, is expanding with $100 million in new funding from tech investor Andreessen Horowitz and several other venture firms. Since officially launching a year ago, Dyno has struck deals with Novartis, Roche and Sarepta Therapeutics to aid their efforts to develop more efficient delivery of gene therapy. But even after doubling in size to 50 employees, the company hasn't been able to keep up...
Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $100m in Series A financing. The round was led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital. Founding investors Polaris Partners, CRV and KdT Ventures all participated in the round. As part of the Series A financing, Jorge Conde, General Partner at Andreessen Horowitz, joined the company’s board of directors. Led by Eric Kelsic, PhD, founder and CEO, Dyno T...